Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmaron has completed the acquisition of Bridge Laboratories China (Bridge), a contract research organization in China providing western standard GLP-compliant toxicology services. The strategic acquisition strengthens Pharmaron's position in the fast-growing pharmaceutical CRO industry.
Subscribe to our email newsletter
The company said that with this acquisition, it becomes the first integrated CRO in China supporting clients with drug discovery and development processes in support of IND filings. Bridge Laboratories China is the only preclinical CRO laboratory in China whose data have been accepted by both the FDA and EMEA, as part of successful regulatory filings.
Boliang Lou, chairman and CEO of Pharmaron, said: “Pharmaron has built an exceptional team of scientists specialised in the areas of discovery and process chemistry, biology, DMPK, pharmacology and GMP manufacturing.
“The acquisition of Bridge Laboratories China enhances our drug R&D service capabilities by adding world-class expertise in western standard GLP-compliant toxicology and safety pharmacology to our diverse service portfolio. Pharmaron is now the first CRO in China to provide fully integrated drug discovery and development services, from discovery chemistry to IND filings.”
Tom Oakley, CEO of Bridge, said: “As a premier provider of drug discovery services, Pharmaron was an ideal partner given the company’s diverse customer base of leading biotech and pharmaceutical companies. The addition of Bridge’s US GLP-compliant toxicology expertise will make Pharmaron the first company in China to provide truly integrated drug development services from discovery to IND.”